EP1916002A4 - Method for prevention of degradation of thermally unstable substance - Google Patents

Method for prevention of degradation of thermally unstable substance

Info

Publication number
EP1916002A4
EP1916002A4 EP06782153A EP06782153A EP1916002A4 EP 1916002 A4 EP1916002 A4 EP 1916002A4 EP 06782153 A EP06782153 A EP 06782153A EP 06782153 A EP06782153 A EP 06782153A EP 1916002 A4 EP1916002 A4 EP 1916002A4
Authority
EP
European Patent Office
Prior art keywords
degradation
prevention
thermally unstable
unstable substance
substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP06782153A
Other languages
German (de)
French (fr)
Other versions
EP1916002B1 (en
EP1916002A1 (en
Inventor
Hiroyuki Asada
Akio Kimura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of EP1916002A1 publication Critical patent/EP1916002A1/en
Publication of EP1916002A4 publication Critical patent/EP1916002A4/en
Application granted granted Critical
Publication of EP1916002B1 publication Critical patent/EP1916002B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP06782153.8A 2005-08-02 2006-08-02 Method for prevention of degradation of thermally unstable substance Active EP1916002B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005223862 2005-08-02
PCT/JP2006/315284 WO2007015510A1 (en) 2005-08-02 2006-08-02 Method for prevention of degradation of thermally unstable substance

Publications (3)

Publication Number Publication Date
EP1916002A1 EP1916002A1 (en) 2008-04-30
EP1916002A4 true EP1916002A4 (en) 2010-04-07
EP1916002B1 EP1916002B1 (en) 2014-03-05

Family

ID=37708790

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06782153.8A Active EP1916002B1 (en) 2005-08-02 2006-08-02 Method for prevention of degradation of thermally unstable substance

Country Status (5)

Country Link
US (2) US8030349B2 (en)
EP (1) EP1916002B1 (en)
JP (3) JP2011057717A (en)
ES (1) ES2460967T3 (en)
WO (1) WO2007015510A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2460967T3 (en) * 2005-08-02 2014-05-16 Santen Pharmaceutical Co., Ltd. Method for preventing degradation of a thermally unstable substance
EP2123278B1 (en) * 2007-02-07 2013-01-09 Teika Pharmaceutical Co., Ltd. Eye drop preparation comprising latanoprost
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
EP2269575A1 (en) * 2009-06-30 2011-01-05 Santen Pharmaceutical Co., Ltd Method for improving bioavailability of latanoprost
WO2018033854A1 (en) 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma
JP7043275B2 (en) * 2018-02-02 2022-03-29 東邦チタニウム株式会社 Molten salt electrolysis method, molten metal manufacturing method, and molten salt electrolysis tank

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767154A (en) * 1991-02-07 1998-06-16 Allergan 5-trans-prostaglandins of the F series and their use as ocular hypotensives
WO2000018316A2 (en) * 1998-09-25 2000-04-06 Alcon Laboratories, Inc. Sustained release, and comfortable ophthalmic composition and method for ocular therapy
US20020002185A1 (en) * 1997-03-17 2002-01-03 Reed Kenneth Warren Compositions and methods for reducing ocular hypertension
WO2003105847A1 (en) * 2002-06-14 2003-12-24 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
WO2004013119A1 (en) * 2002-08-05 2004-02-12 Allergan, Inc. The 9, 11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4305947A (en) 1980-08-26 1981-12-15 Survival Technology, Inc. Stable aqueous solutions of pralidoxime salts
JP2849922B2 (en) * 1989-05-26 1999-01-27 吉富製薬株式会社 Liquid composition containing plasminogen activator
US5288754A (en) * 1992-02-04 1994-02-22 Allergan, Inc. Polar C-1 esters of prostaglandins
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
JP3170619B2 (en) 1995-04-20 2001-05-28 参天製薬株式会社 Planoprofen ophthalmic solution containing organic amine
AR002194A1 (en) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany COMPUTERIZED INSTRUMENT FOR THE ANALYSIS OF MOVEMENT.
CN1146423C (en) * 1998-07-14 2004-04-21 阿尔康实验室公司 Prostaglandin product
US6235781B1 (en) 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
JP2003146881A (en) 2001-11-14 2003-05-21 Toyo Pharmar Kk Anti-allergic ophthalmic preparation
ATE357219T1 (en) * 2002-01-25 2007-04-15 Glaxo Group Ltd DOSAGE FORMS FOR DNA
JP4431817B2 (en) 2002-03-08 2010-03-17 第一三共株式会社 Eye drops containing tetrazole derivatives
JP4314429B2 (en) 2002-08-23 2009-08-19 参天製薬株式会社 Stable ophthalmic solution containing latanoprost as an active ingredient
CN100361661C (en) 2002-08-23 2008-01-16 参天制药株式会社 Stable eye lotion containing latanoprost as active ingredient
BRPI0414149A (en) * 2003-09-05 2006-10-31 Novartis Ag compositions comprising benzo (g) -quinoline derivatives and prostaglandin derivatives
ES2331313T3 (en) * 2003-11-07 2009-12-29 Senju Pharmaceutical Co., Ltd. PHARMACEUTICAL COMPOSITION CONTAINING PROSTAGLANDIN.
JP2004307491A (en) 2004-03-24 2004-11-04 Taisho Pharm Ind Ltd Skin care preparation for external use containing heparinoid
ES2460967T3 (en) * 2005-08-02 2014-05-16 Santen Pharmaceutical Co., Ltd. Method for preventing degradation of a thermally unstable substance

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767154A (en) * 1991-02-07 1998-06-16 Allergan 5-trans-prostaglandins of the F series and their use as ocular hypotensives
US20020002185A1 (en) * 1997-03-17 2002-01-03 Reed Kenneth Warren Compositions and methods for reducing ocular hypertension
WO2000018316A2 (en) * 1998-09-25 2000-04-06 Alcon Laboratories, Inc. Sustained release, and comfortable ophthalmic composition and method for ocular therapy
US6486208B1 (en) * 1998-09-25 2002-11-26 Alcon Laboratories, Inc. Sustained release, and comfortable opthalmic composition and method for ocular therapy
WO2003105847A1 (en) * 2002-06-14 2003-12-24 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
WO2004013119A1 (en) * 2002-08-05 2004-02-12 Allergan, Inc. The 9, 11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma

Also Published As

Publication number Publication date
EP1916002B1 (en) 2014-03-05
JP2012140459A (en) 2012-07-26
JP2014141534A (en) 2014-08-07
US8324271B2 (en) 2012-12-04
WO2007015510A1 (en) 2007-02-08
ES2460967T3 (en) 2014-05-16
JP2011057717A (en) 2011-03-24
EP1916002A1 (en) 2008-04-30
JP5593345B2 (en) 2014-09-24
US20090264523A1 (en) 2009-10-22
US20110295034A1 (en) 2011-12-01
US8030349B2 (en) 2011-10-04

Similar Documents

Publication Publication Date Title
ZA200805297B (en) Method of using ß-hydroxy-ß-methylbutyrate
IL191997A0 (en) Inhibitors of iap
HUE042590T2 (en) Method for improving the bioavailability of curcumin
GB0514601D0 (en) Parsing method
EP1911733A4 (en) Method for forming masonry unit
ZA200902546B (en) Aroma stabilizing method
EP1855729A4 (en) Method of sterilization
IL189144A0 (en) Method for isolating 5-substituted tetrazoles
GB0516148D0 (en) Method of integrating an element
EP1916002A4 (en) Method for prevention of degradation of thermally unstable substance
EP1946857A4 (en) Method for modification of asbestos
GB0517929D0 (en) Method of printing
EP1964538A4 (en) Preparation method of pharmaceutials
GB2424853B (en) Method of printing
EP1940450A4 (en) Method of modulation
PL1841521T3 (en) Encapsulation method for compounds
EP1950205A4 (en) Method for stabilization of isoxazole compound
IL190139A0 (en) Method for the determination of poloxamers
GB2428638B (en) Method of estimating alignment
AP2007004297A0 (en) Method of combating bugs
MY144154A (en) Method of combating infection
EP1932923A4 (en) Method for determination of effective dose of methotrexate
GB2433394B (en) Method of frame storage
GB0522644D0 (en) New method for antagonisation of anticoagulants
EP1950293A4 (en) Method for prediction of effectiveness of rar- agonist

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080208

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20100309

17Q First examination report despatched

Effective date: 20100527

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602006040518

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61K0047180000

Ipc: A61K0009000000

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/00 20060101AFI20130827BHEP

Ipc: A61K 31/5575 20060101ALI20130827BHEP

Ipc: A61K 47/18 20060101ALI20130827BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20131004

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 654364

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140315

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602006040518

Country of ref document: DE

Effective date: 20140417

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2460967

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20140516

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 654364

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140305

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20140305

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140305

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140305

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140305

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140305

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140305

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140305

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140705

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140605

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140305

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140305

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140305

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140305

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140305

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140305

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140305

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602006040518

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140707

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140305

26N No opposition filed

Effective date: 20141208

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602006040518

Country of ref document: DE

Effective date: 20141208

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140305

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140802

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140831

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140831

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140305

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140802

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140606

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20060802

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20200729

Year of fee payment: 15

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210802

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20230711

Year of fee payment: 18

Ref country code: GB

Payment date: 20230629

Year of fee payment: 18

Ref country code: ES

Payment date: 20230901

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230703

Year of fee payment: 18

Ref country code: DE

Payment date: 20230627

Year of fee payment: 18